NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/10/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,094.57 mln
Float44.16 mln
Earnings Date08/06/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
36
/ 100
Underperforming
Debt / Equity
0.01
Debt-free
ROE
-48.68
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Cullinan Therapeutics is a Cambridge, Massachusetts-based drug development company focused on finding new treatments for cancer and autoimmune conditions. The company is currently running multiple clinical trials, testing several experimental medicines including targeted therapies for blood cancers, lung cancer, and autoimmune diseases. Cullinan works alongside a number of partners, including Taiho Pharmaceutical and Chongqing Genrix Biopharmaceutical, to bring its treatments to patients. Founded in 2016, the company operates under its current name following a rebranding in 2024.
